SIBN Stock Analysis: Buy, Sell, or Hold?
SIBN - SI-BONE, Inc. Common Stock
$13.12
0.11 (0.85%)
▲
5d:
+2.18%
30d:
-10.81%
90d:
-33.47%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
SIBN is down 4.1% this week, but smart money is accumulating calls. Top strike: $12.5 2026-05-15 with 150 OI. Call ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When SIBN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SIBN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: SIBN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: SIBN is currently trading at $13.12, which is considered slightly low relative to its 30-day fair value range of $12.62 to $14.98.
Technical Outlook: Technically, SIBN is in a strong downtrend. The price is approaching resistance at $13.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.00 (+98.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SIBN is in a strong downtrend. The price is approaching resistance at $13.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.00 (+98.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$12.62 -
$14.98
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 98.2% below Wall St target ($26.00)
Fair Price Analysis
30-Day Fair Range
$12.62 -
$14.98
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$1.13
(8.6%)
Support & Resistance Levels
Support Level
$12.15
Resistance Level
$13.49
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.40
Wall Street Target
$26.00
(+98.2%)
Revenue Growth (YoY)
15.0%
Profit Margin
-9.4%
Share & Embed Analysis
Last updated: April 02, 2026 5:19 PM ET
Data refreshes hourly during market hours. Next update: 6:19 PM
Data refreshes hourly during market hours. Next update: 6:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SIBN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Mika Nishimura
SELL
4100 shares
2026-03-12
Anshul Maheshwari
SELL
21528 shares
2026-02-17
Anthony J Recupero
SELL
21049 shares
2026-02-17
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 52 HOLD |
